Skip to main content
. 2020 Dec 22;13(2):e12889. doi: 10.15252/emmm.202012889

Figure 6. Loss of CSF‐1R reduces BBB integrity.

Figure 6

  • A–C
    (A) IHC of ALSP patient post‐mortem tissue for amyloid‐β (green) and CLD5 (red), (B) human IgG (green) and PDGFRβ (red), (C) GFAP (green) and CLD5 (red). ΔA781_N783 and P824R indicate the CSF‐1R variant present.
  • D–H
    (D) Iba1 (green) and GFAP (red), (E) amyloid‐β (green) and CD68 (red), (F) CD163 (green) and CLD5 (red), (G) fibrinogen (green) and CLD5 (red) and (H) FLAIR imaging of an ALSP patient with the ΔA781_N783 CSF‐1R variant. ΔA781_N783 and P824R indicate the CSF‐1R variant present.
  • I
    T1‐weighted DCE‐MRI of an ALSP patient with the ΔA781_N783 CSF‐1R variant. Colormetric scale indicates the slope of the quantified Gd‐BOPTA accumulation, as an indicator of BBB permeability.
  • J
    Susceptibility weighted imaging (SWI) of an ALSP patient with the ΔA781_N783 CSF‐1R variant showing iron deposition.

Data information: Note that Fig 6C and F are shown again in Fig EV1 for ease of comparison.